» Articles » PMID: 23361940

Altered PTEN, ATRX, CHGA, CHGB, and TP53 Expression Are Associated with Aggressive VHL-associated Pancreatic Neuroendocrine Tumors

Overview
Journal Horm Cancer
Date 2013 Jan 31
PMID 23361940
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Von Hippel-Lindau (VHL) syndrome is an inherited cancer syndrome in which 8-17 % of germline mutation carriers develop pancreatic neuroendocrine tumors (PNETs). There is limited data on prognostic markers for PNETs other than Ki-67, which is included in the World Health Organization classification system. Recently, specific genes and pathways have been identified by whole exome sequencing which may be involved in the tumorigenesis of PNETs and may be markers of disease aggressiveness. The objective of this study was to identify molecular markers of aggressive disease in VHL-associated PNETs. The protein expression of eight genes (PTEN, CHGA, CHGB, ATRX, DAXX, CC-3, VEGF, and TP53) was analyzed in PNETs by immunohistochemistry and compared to clinical data, VHL genotype, functional imaging results, and pathologic findings. Subcellular distribution of phosphatase and tensin (PTEN), chromogranin A (CHGA), and alpha thalassemia/mental retardation syndrome X-linked (ATRX) were significantly different by WHO classifications (p ≤ 0.05). There was decreased PTEN nuclear to cytoplasmic ratio (p < 0.01) and decreased CHGA nuclear expression (p = 0.03) in malignant samples as compared to benign. Lower cytoplasmic chromogranin B (CHGB) expression (p = 0.03) was associated with malignant tumors and metastasis. Higher nuclear expression of PTEN was associated with VHL mutations in exon 3 (p = 0.04). Higher PTEN and CHGB expression was associated with higher FDG-PET avidity (p < 0.05). Cytoplasmic expression of CC-3 was associated with higher serum chromogranin A levels (ρ = 0.72, p = 0.02). Lastly, greater cytoplasmic expression of p53 was associated with metastasis. Our findings suggest that altered PTEN, ATRX, CHGA, and CHGB expression are associated with aggressive PNET phenotype in VHL and may serve as useful adjunct prognostic markers to Ki-67 in PNETs.

Citing Articles

Screening high-risk individuals for primary gastric adenocarcinoma: evaluating progression-free survival probability score in the presence and absence of Rictor expression after gastrectomy.

Wang J, Li Y, Liang S Front Oncol. 2024; 14:1382818.

PMID: 39588299 PMC: 11586260. DOI: 10.3389/fonc.2024.1382818.


Prognostic Biomarkers for Hepatocellular Carcinoma Based on Serine and Glycine Metabolism-related Genes.

Cai X, Xu F, Wang Z, Chen H, Lin S J Clin Transl Hepatol. 2024; 12(3):266-277.

PMID: 38426196 PMC: 10899868. DOI: 10.14218/JCTH.2023.00457.


Identification of hub genes to determine drug-disease correlation in breast carcinomas.

Bhowmick C, Rahaman M, Bhattacharya S, Mukherjee M, Chakravorty N, Dutta P Med Oncol. 2023; 41(1):36.

PMID: 38153604 DOI: 10.1007/s12032-023-02246-9.


The Clinical Impact of Death Domain-Associated Protein and Holliday Junction Recognition Protein Expression in Cancer: Unmasking the Driving Forces of Neoplasia.

Pergaris A, Genaris I, Stergiou I, Klijanienko J, Papadakos S, Theocharis S Cancers (Basel). 2023; 15(21).

PMID: 37958340 PMC: 10650673. DOI: 10.3390/cancers15215165.


Exploring Immune-Related Prognostic Signatures in the Tumor Microenvironment of Colon Cancer.

Cao L, Li T, Ba Y, Chen E, Yang J, Zhang H Front Genet. 2022; 13:801484.

PMID: 35281839 PMC: 8907673. DOI: 10.3389/fgene.2022.801484.


References
1.
Portela-Gomes G, Stridsberg M, Grimelius L, Falkmer U, Falkmer S . Expression of chromogranins A, B, and C (secretogranin II) in human adrenal medulla and in benign and malignant pheochromocytomas An immunohistochemical study with region-specific antibodies. APMIS. 2004; 112(10):663-73. DOI: 10.1111/j.1600-0463.2004.t01-1-apm1121003.x. View

2.
Kloppel G, Perren A, Heitz P . The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci. 2004; 1014:13-27. DOI: 10.1196/annals.1294.002. View

3.
Rotter V, Abutbul H, Ben-Zeev A . P53 transformation-related protein accumulates in the nucleus of transformed fibroblasts in association with the chromatin and is found in the cytoplasm of non-transformed fibroblasts. EMBO J. 1983; 2(7):1041-7. PMC: 555232. DOI: 10.1002/j.1460-2075.1983.tb01543.x. View

4.
Shaulsky G, Goldfinger N, Ben-Zeev A, Rotter V . Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis. Mol Cell Biol. 1990; 10(12):6565-77. PMC: 362933. DOI: 10.1128/mcb.10.12.6565-6577.1990. View

5.
Scopsi L, Sampietro G, Boracchi P, Collini P . Argyrophilia and chromogranin A and B immunostaining in patients with sporadic medullary thyroid carcinoma. A critical appraisal of their prognostic utility. J Pathol. 1998; 184(4):414-9. DOI: 10.1002/(SICI)1096-9896(199804)184:4<414::AID-PATH1229>3.0.CO;2-U. View